OCUL · Insider Trading
Ocular Therapeutix, Inc.
Every open-market purchase and sale reported by OCUL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Todd Anderman | Chief Legal Officer | Sell | −11,984 | −$87.36K |
| 2026-10-06 | Peter Kaiser | Chief Development Officer | Sell | −9,990 | −$70.43K |
| 2026-10-06 | Jeffrey S. Heier | Chief Scientific Officer | Sell | −10,869 | −$76.63K |
| 2026-09-02 | Donald Notman | Chief Operating Officer | Sell | −1,099 | −$11.25K |
| 2026-08-26 | Pravin Dugel | See Remarks | MIXED | −21,649 | −$233.16K |
| 2026-08-26 | Peter Kaiser | Chief Development Officer | Sell | −3,035 | −$32.69K |
| 2026-08-26 | Jeffrey S. Heier | Chief Scientific Officer | Sell | −3,296 | −$35.53K |
| 2026-08-26 | Sanjay Nayak | Chief Strategy Officer | Sell | −1,897 | −$20.45K |
| 2026-06-18 | Pravin Dugel | See Remarks | G | — | — |
| 2026-06-12 | Adrienne L Graves | Director | A | +14,000 | — |
| 2026-06-12 | Jason Shand Robins | Chief Financial Officer | A | +15,441 | — |
| 2026-06-12 | Merilee Raines | Director | A | +14,000 | — |
| 2026-06-12 | Charles M Warden | Director | A | +14,000 | — |
| 2026-06-12 | Seung Suh Hong | Director | A | +14,000 | — |
| 2026-06-12 | Richard L Md Lindstrom | Director | A | +14,000 | — |
| 2026-06-12 | Leslie J. Williams | Director | A | +14,000 | — |
| 2026-06-05 | Nadia Waheed | Chief Medical Officer | Sell | −14,828 | −$122.63K |
| 2026-05-28 | Sanjay Nayak | Chief Strategy Officer | Sell | −1,858 | −$15.24K |
| 2026-05-28 | Jeffrey S. Heier | Chief Scientific Officer | Sell | −3,018 | −$24.75K |
| 2026-05-28 | Peter Kaiser | Chief Development Officer | Sell | −2,967 | −$24.33K |
| 2026-05-28 | Pravin Dugel | See Remarks | MIXED | −21,156 | −$173.48K |
| 2026-04-13 | Pravin Dugel | See Remarks | G | — | — |
| 2026-02-25 | Jeffrey S. Heier | Chief Scientific Officer | Sell | −3,057 | −$25.31K |
| 2026-02-25 | Peter Kaiser | Chief Development Officer | Sell | −2,810 | −$23.27K |
| 2026-02-25 | Sanjay Nayak | Chief Strategy Officer | Sell | −1,759 | −$14.56K |
| 2026-02-25 | Pravin Dugel | See Remarks | Sell | −20,056 | −$166.06K |
| 2026-02-24 | Nadia Waheed | Chief Medical Officer | Sell | −3,510 | −$27.17K |
| 2026-02-24 | Richard L Md Lindstrom | Director | Buy | +60,229 | +$461.35K |
| 2026-02-17 | Nadia Waheed | Chief Medical Officer | Sell | −7,863 | −$71.08K |
| 2026-02-17 | Sanjay Nayak | Chief Strategy Officer | Sell | −10,348 | −$93.55K |
| 2026-02-17 | Donald Notman | Chief Operating Officer | Sell | −11,446 | −$103.47K |
| 2026-02-17 | Pravin Dugel | See Remarks | Sell | −124,882 | −$1.13M |
| 2026-02-04 | Donald Notman | Chief Operating Officer | Sell | −11,490 | −$101.40K |
| 2026-01-26 | David Wayne Robinson | Global CCO | A | +136,000 | — |
| 2026-01-22 | Jason Shand Robins | Interim CFO | A | +33,000 deriv. | — |
| 2026-01-06 | Sanjay Nayak | Chief Strategy Officer | A | +64,900 | — |
| 2026-01-06 | Peter Kaiser | Chief Development Officer | A | +79,112 | — |
| 2026-01-06 | Namrata Saroj | Chief Business Officer | A | +79,112 | — |
| 2026-01-06 | Jeffrey S. Heier | Chief Scientific Officer | A | +79,112 | — |
| 2026-01-06 | Donald Notman | See Remarks | A | +79,112 | — |
| 2026-01-06 | Nadia Waheed | Chief Medical Officer | A | +79,112 | — |
| 2026-01-06 | Steve Lawrence Meyers | Chief Commercial Officer | A | +64,900 | — |
| 2026-01-06 | Todd Anderman | Chief Legal Officer | A | +64,900 | — |
| 2025-11-26 | Sanjay Nayak | Chief Strategy Officer | Sell | −1,878 | −$22.61K |
| 2025-11-26 | Peter Kaiser | Chief Development Officer | Sell | −3,007 | −$36.14K |
| 2025-11-26 | Pravin Dugel | See Remarks | MIXED | −19,530 | −$235.14K |
| 2025-11-26 | Jeffrey S. Heier | Chief Scientific Officer | Sell | −3,469 | −$41.77K |
| 2025-11-07 | Namrata Saroj | Chief Business Officer | Sell | −25,865 | −$277.79K |
| 2025-10-10 | Todd Anderman | Chief Legal Officer | Sell | −11,132 | −$137.37K |
| 2025-10-06 | Jeffrey S. Heier | Chief Scientific Officer | Sell | −10,502 | −$115.94K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Pravin Dugel | See Remarks | 3,270,332 | $20.57M |
| Charles M Warden | Director | 475,585 | $2.99M |
| Donald Notman | Chief Operating Officer | 366,529 | $2.31M |
| Sanjay Nayak | Chief Strategy Officer | 326,898 | $2.06M |
| Jeffrey S. Heier | Chief Scientific Officer | 307,457 | $1.93M |
| Richard L Md Lindstrom | Director | 304,492 | $1.92M |
| Nadia Waheed | Chief Medical Officer | 300,079 | $1.89M |
| Namrata Saroj | Chief Business Officer | 254,620 | $1.60M |
| Peter Kaiser | Chief Development Officer | 254,388 | $1.60M |
| Steve Lawrence Meyers | Chief Commercial Officer | 217,628 | $1.37M |
| Todd Anderman | Chief Legal Officer | 140,484 | $883.64K |
| David Wayne Robinson | Global CCO | 136,000 | $855.44K |
| Jason Shand Robins | Chief Financial Officer | 68,097 | $428.33K |
| Leslie J. Williams | Director | 65,433 | $411.57K |
| Adrienne L Graves | Director | 64,000 | $402.56K |
| Seung Suh Hong | Director | 60,933 | $383.27K |
| Merilee Raines | Director | 60,933 | $383.27K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OCUL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.